DailyStocks Stock Article Search

https://www.fool.com/investing/2024/02/18/2-top-growth-stocks-to-buy-with-1000-right-now/?source=iedfolrf0000001 Feb 17, 2024 - Even a modest starting investment in the right stocks could pay off in the years ahead. 0

https://www.fool.com/investing/2024/06/07/stock-split-watch-3-growth-stocks-that-could-be-ne/?source=iedfolrf0000001 Jun 07, 2024 - Success has some downsides, including a much higher stock price. 0

https://www.fool.com/investing/2024/08/03/is-regeneron-pharmaceuticals-due-for-a-stock-split/?source=iedfolrf0000001 Aug 03, 2024 - Would a stock split help lead Regeneron Pharmaceuticals shares higher? 0

https://www.fool.com/investing/2023/12/14/3-stocks-to-buy-before-2024-that-can-set-you-up/?source=iedfolrf0000001 Dec 14, 2023 - These stocks are still relatively cheap, but don't expect them to stay that way for long. 0

https://www.fool.com/investing/2024/02/21/2-no-brainer-biotech-stocks-to-buy-right-now/?source=iedfolrf0000001 Feb 21, 2024 - These stocks are used to beating the market. 0

https://www.fool.com/investing/2024/03/28/stock-split-watch-are-these-2-top-growth-stocks/?source=iedfolrf0000001 Mar 28, 2024 - Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. 0

https://www.fool.com/data-news/2024/05/02/regenerons-q1-earnings-insight/?source=iedfolrf0000001 May 02, 2024 - The biotech's top-line dip can be traced to a loss of COVID-related revenues. 0

https://www.fool.com/investing/2024/05/16/these-2-no-brainer-growth-stocks-are-breaking-new/?source=iedfolrf0000001 May 16, 2024 - The future keeps getting brighter for these companies. 0

https://www.fool.com/investing/2024/07/27/bull-market-buys-2-growth-stocks-to-own-for-the/?source=iedfolrf0000001 Jul 27, 2024 - These companies are no strangers to beating the market. 0

https://www.zacks.com/stock/news/2193528/eyepoint-eypt-surges-178-on-upbeat-phase-ii-eye-disease-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193528 Dec 05, 2023 - EyePoint (EYPT) announces positive top-line data from the phase II study of its investigational candidate, EYP-1901, in the treatment of wet age-related macular degeneration. The stock rallies 178%. 0